01—Abstract
Summary
Summary of the 10-Q filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Bristol-Myers Squibb's Q3 2025 10-Q shows a quarter with GAAP net earnings attributable to BMS of $2.2 billiona ($1.08 diluted EPS) versus $1.2 billion ($0.60) a year ago, while total revenues rose 3% to $12.2 billion.
Growth was driven by the Growth Portfolio, up 18% to $6.9 billionb, with strong contributions from Opdivo, Reblozyl, Camzyos, Breyanzi and Eliquis (U.S. +29%). Offsetting this, the Legacy Portfolio fell 12% as generics eroded Revlimid (-59%), Pomalyst (-25%), Sprycel and Abraxane. Year-to-date revenues declined 1% to $35.7 billion, with U.S. revenues down 3% amid lower average net selling prices and the Medicare Part D redesign, which also pushed up GTN adjustments to 47% of gross sales in the quarter.
The headline GAAP earnings improvement is largely a function of lower non-cash amortization of acquired intangibles (down to $831 millionc from $2.4 billion) and lower one-time Acquired IPRD charges year-to-date ($2.3 billion versus $13.3 billion in 2024, which included Karuna). Non-GAAP EPS, which excludes these items, was $1.63 in the quarter, down from $1.80, reflecting higher IPRD charges in Q3 2025 tied to the BioNTech, Philochem and SystImmune deals. Cost discipline is clearly visible: SG&A fell 19% year-to-date and R&D fell 8%, supported by the ongoing strategic productivity initiative, which management expects to deliver about $2.0 billion in annual savings by the end of 2027.
Balance sheet and cash generation remained solid. Operating cash flow was $12.2 billiond year-to-date, funding $3.8 billion of dividends and $2.2 billion of business development payments, while net debt improved by $6.4 billion to $32.1 billion.
Cash and equivalents rose to $15.7 billion. Key risks flagged include U.S. drug-pricing policy (IRA negotiation, the most-favored-nation executive order), generic entry for Pomalyst in the U.S. in March 2026, Eliquis European generic erosion, and several material litigation matters, including the Celgene securities class action now subject to a settlement in principle.
02—Key points
Key Highlights
- Q3 2025 total revenues rose 3% to $12.2B, led by the Growth Portfolio (+18% to $6.9B) with Opdivo, Breyanzi, Camzyos, Reblozyl and Eliquis (U.S. +29%) as the main contributors.
- GAAP diluted EPS was $1.08 in Q3 2025 versus $0.60 a year ago; year-to-date GAAP EPS was $2.93 versus a loss of $(4.45), mainly due to far lower Acquired IPRD charges and amortization.
- Non-GAAP diluted EPS fell to $1.63 in Q3 2025 from $1.80, pressured by a $350M Philochem upfront and a $250M SystImmune milestone charge recorded as Acquired IPRD.
- Legacy Portfolio revenue declined 12% in Q3 as generic erosion hit Revlimid (-59%), Pomalyst (-25%), Sprycel (-59%) and Abraxane (-71%).
- Year-to-date operating cash flow of $12.2B (up from $10.8B) and a $6.4B reduction in net debt to $32.1B strengthen financial flexibility despite $3.8B in dividends.
- Cost savings from the strategic productivity initiative drove SG&A down 19% year-to-date, and management targets about $2.0B in annual savings by end-2027.
- Pricing pressure is intensifying: U.S. average net selling prices fell 5% year-to-date, and GTN adjustments rose to 47% of gross sales in Q3 from 46%, driven by Medicare Part D redesign effects.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 30, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $12.22B$11.89B | +2.8% |
| Cost of Revenue | $3.44B$2.96B | +16.2% |
| Gross Profit | $8.79B$8.94B | −1.7% |
| R&D Expenses | $2.53B$2.37B | +6.5% |
| SG&A Expenses | $1.79B$1.98B | −9.8% |
| Operating Expenses | $9.11B$10.22B | −10.8% |
| Net Income | $2.20B$1.21B | +81.8% |
| EPS (Basic) | $1.08$0.60 | +80.0% |
| EPS (Diluted) | $1.08$0.60 | +80.0% |
| Shares Outstanding (Basic) | 2.04B2.03B | +0.4% |
| Shares Outstanding (Diluted) | 2.04B2.03B | +0.4% |
05—Questions
Frequently Asked Questions
Why did GAAP earnings improve so sharply compared with the prior year?
Most of the swing comes from non-cash and one-time items. Year-to-date 2024 included a $12.1B Acquired IPRD charge for the Karuna acquisition, whereas 2025 Acquired IPRD totals $2.3B. Amortization of acquired intangibles also fell by $4.7B year-to-date, mainly because the Revlimid marketed product right was fully amortized in Q4 2024. Operationally, the improvement is smaller, and non-GAAP earnings are actually down year-to-date on a per-share basis only relative to the depressed 2024 base, so investors should focus on underlying trends.
How much revenue is at risk from generic competition and upcoming patent expirations?
The Legacy Portfolio already fell $3.1B year-to-date (-16%), with Revlimid down $2.1B. Generic pomalidomide (Pomalyst) is expected to enter the U.S. in March 2026, and Eliquis faces European generic entry in several countries despite ongoing litigation. Revlimid volume-limited generic licenses become unrestricted on January 31, 2026, which could further accelerate erosion. Growth Portfolio products and Eliquis in the U.S. are the main offsets.
What is the outlook for drug pricing policy and how could it affect BMS?
The IRA Medicare price for Eliquis takes effect January 1, 2026, and Pomalyst has been selected for government price negotiation starting in 2027. The May 2025 most-favored-nation executive order and related letters to manufacturers add further uncertainty. Management states these changes could materially affect U.S. pricing, reimbursement and results, and the 340B cash rebate case is pending in the D.C. Circuit. The Q3 U.S. GTN rate of 54% highlights how much pricing pressure is already embedded in results.
Is BMS's balance sheet and capital allocation strong enough to support its dividend and business development?
Yes, in the near term. Cash and marketable securities rose to $16.9B against $48.7B of total debt, and net debt improved to $32.1B from $38.5B. Year-to-date operating cash flow of $12.2B covered $3.8B in dividends and $2.2B in acquisition and milestone payments. The company has a $5.0B revolving credit facility undrawn and $5.0B remaining under its buyback authorization, but it has not repurchased shares this year. Pending commitments include the $1.5B Orbital Therapeutics acquisition, $2.0B of BioNTech anniversary payments from 2026 to 2028, and the $1.3B BioArctic milestone pool.
What are the most significant legal risks disclosed in the filing?
The most material items are the Celgene securities class action, now subject to a settlement in principle (court approval pending), and several CVR-related suits, including a claim tied to a potential $6.4B CVR obligation for Breyanzi. The Mirati CVR milestone fair value rose by $336M year-to-date, reflecting higher probability of the regulatory milestone. Litigation and other settlements expense was $424M year-to-date. The Eliquis European patent challenges, Revlimid and Thalomid antitrust claims, and the IRA constitutional challenge (affirmed against BMS by the Third Circuit in September 2025) are also significant. Management says none is expected to have a material adverse effect on financial position or liquidity, though results could be affected in a given period.
06—Continue